ABT Is Down 22% After 500 Days. What History Says Now

ABT Is Down 22% After 505 Days. What History Says About Recovery

Abbott Laboratories (ABT) is down 22% from its all-time high as of July 28, 2026, having just exited the red zone after spending approximately 17 months (505 days) in drawdown. The Drawdown Severity Score™ has improved to 4.7, placing the stock in the Significant severity level. In 12 comparable prior drops of 20% or more, the stock took an average of 642 days to recover.

Abbott Laboratories Exits the Red Zone

When a high-quality, defensive asset like Abbott Laboratories transitions from the red zone to the yellow zone, it signals a potential shift in institutional sentiment. Unlike high-beta technology stocks that can bounce erratically out of deep drawdowns, large-cap healthcare providers typically undergo a more structured consolidation process. A recovery from the red zone indicates that the selling pressure has stabilized, and the market is beginning to price in long-term fundamental support rather than short-term panic.

Our data shows that stocks transitioning to the yellow zone often experience a period of range-bound trading before establishing a clearer upward trajectory. This pattern contrasts sharply with more speculative sectors, where a transition out of the red zone can trigger rapid short squeezes or sudden reversals. For Abbott Laboratories, this transition marks a critical technical milestone in its 505-day recovery journey.

Analyzing the Severity Pivot: The Exact Numbers

As of July 28, 2026, Abbott Laboratories is trading at $107.32, representing a -22.4% drawdown from its all-time high of $138.33. The stock has spent 505 days in this drawdown cycle, reflecting a prolonged period of consolidation and correction. The recent improvement in the Drawdown Severity Score™ to 4.7 moves the stock out of the high-risk red zone and into the Significant severity level, represented by the yellow zone.

This transition indicates that while the stock remains in a deep pullback, the immediate downside momentum has weakened. The severity score of 4.7 reflects a moderate-to-high risk profile, but one that is markedly improved from the severe distress indicated by the previous red-zone classification.

The table below outlines the current drawdown metrics for Abbott Laboratories as of the data date.

Peer Comparison: Recovery Profiles in Healthcare

To understand Abbott's recovery, we must compare its trajectory to peers in the medical technology and healthcare sectors. According to analysis by Trefis, competitors like Boston Scientific (BSX) and ResMed (RMD) offer different risk and return profiles, with some peers demonstrating faster recovery cycles due to fewer regulatory or litigation headwinds. When medical device companies experience deep drawdowns, their recovery timelines are heavily influenced by product approval cycles and legal resolutions.

The table below outlines how Abbott's current drawdown parameters compare to typical averages for large-cap medical technology peers during similar market corrections.

While Abbott has taken longer than the typical peer average to exit the red zone, its established product pipeline provides a more predictable recovery path than smaller, single-product medical device companies. The transition to a severity score of 4.7 highlights this slow but steady stabilization.

Abbott's Historical Drawdown Record

Our data shows that Abbott Laboratories has a highly stable historical profile, making its current 505-day drawdown an unusual event. Over the lifetime of the asset, we have tracked 297 total historical drawdown events. The average max drawdown across all of these events is just -4.4%, with an average drawdown duration of 46 days.

These historical averages demonstrate that Abbott Laboratories rarely experiences deep or prolonged corrections. However, when the stock does enter a severe correction, the recovery process is historically lengthy. Abbott has dropped 20% or more from its all-time high only 12 times in its history.

In these 12 comparable prior drops, the average duration of the drawdown was 642 days. This means that the current drawdown of 505 days is actually tracking ahead of the historical average for corrections of this magnitude.

The table below provides a detailed breakdown of Abbott's historical drawdown metrics to put the current cycle into perspective.

Comparing the current 505-day duration to the historical 642-day average suggests that Abbott is entering the later stages of its typical deep correction cycle.

Fundamental Drivers and News Catalysts

The current drawdown was initiated by a combination of mixed financial guidance and legal challenges. According to Yahoo Finance, Abbott Laboratories fell initially as guidance and litigation concerns overshadowed its underlying growth. These litigation concerns, particularly surrounding its infant formula division, created a prolonged overhang on the stock, driving it to 52-week lows, as reported by Stocktwits.

During this period of uncertainty, some analysts questioned the stock's near-term outlook. The Globe and Mail published an analysis discussing whether Abbott stock remained attractive after its earnings and guidance update, reflecting the mixed sentiment that kept the stock in the red zone. Additionally, Simply Wall St noted that the stock could be 14% undervalued on mixed earnings and growth focus, suggesting that the market's reaction may have been overextended relative to the company's long-term business fundamentals.

The catalyst for the recent recovery and the subsequent improvement in the severity score was a major fundamental update. According to Investor's Business Daily, Abbott boosted its 2026 profit outlook, causing the stock to climb 11% and strike a three-month high. This positive guidance revision helped offset the lingering litigation worries.

Furthermore, TradingView reported that Abbott is successfully riding key innovation trends in diabetes, oncology, and heart care. The strong performance of its continuous glucose monitoring systems and other cardiovascular devices has provided the revenue growth necessary to support the stock's recovery.

Looking Ahead: The Remaining Path to the Green Zone

While the transition to the Significant severity level is a positive technical signal, Abbott Laboratories still has a long path ahead to reach its previous highs. To fully recover to its all-time high of $138.33, the stock must gain approximately 28.9% from its current price of $107.32.

As the stock continues its recovery, the Drawdown Severity Score™ will continue to adjust. For the stock to transition from the Significant severity level (yellow zone) to the low-risk green zone, it will need to sustain its upward momentum and clear key technical resistance levels.

Investors tracking Abbott Laboratories should monitor the progress of its core medical device segments and any updates regarding its outstanding litigation. While history shows that recoveries from 20%+ drawdowns take time, the transition out of the red zone is the first major step toward a full recovery.